Thiazolidines are five-member heterocyclic having sulfur, nitrogen, and oxygen atoms in their ring structure and exhibiting potent as well as wide range of pharmacological activities. In this minireview, recent updates on synthesis and pharmacological evaluations of molecules based on 2,4-thiazolidine and rhodanine are discussed.
Introduction
Five-membered heterocyclic molecules containing thiazole nucleus with carbonyl group on fourth carbon such as rhodanine and 2,4-thiazolidinedione derivatives have broad spectrum of pharmacological activities. In past two decades, rhodanines and 2,4-thiazolidinediones have emerged as potent antidiabetic agents. Some of them are clinically used such as ciglitazone, englitazone, pioglitazone, glitazones, epalrestat, and troglitazone for the treatment of type 2 diabetes mellitus and related complications. This is the reason why investigation/molecular modification and pharmacological evaluation of these molecules have attracted special attention of synthetic chemists and pharmacologists, respectively. In recent years, a number of synthetic/pharmacological protocols based on these molecules have been emerged extensively and in witness available in the literature. These multifaceted molecules exhibit varied type of biological activities. Some recent developments in synthesis and pharmacology of these molecules are discussed in this section.
Recent Developments in Rhodanine Pharmacology
In 1997, Boyd carried out a study based on rhodaninecontaining molecules of pharmaceutical interest and found pharmacological importance of these molecules is limited because of poor solubility of rhodanine derivatives in water (exception of rhodanine-3-acetic acids). However, these compounds exhibit a broad range of significant biological activities [1] . Rhodanine-3-acetic acid (RAA) 1 was prepared by Korner [2] in 1908, and Knoevenagel condensation products of the acid with various aldehydes, namely, [(5Z)-(5-benzylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl)]acetic acids 2 were reported in the same year [3] . From 1960 onwards, studies revealed that such type of molecule exhibit potential antimycobacterial [4, 5] , antifungal [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , pesticidal [16] [17] [18] , antihypertensive [19] , and antineoplastic [20, 21] activities. Their NMR characterization performed in 1982 [22] . In 2006, similar derivatives have been prepared under microwave irradiation [23] . Further, the Knoevenagel products of rhodanine-3-acetic acid with pyridinecarbaldehydes were prepared in 1961 and they possess potential antibacterial and antifungal activities [8] . {(5Z)-[4-Oxo-5-(pyridin-2-ylmethylidene)-2-thioxo-1,3-thiazolidin-3-yl]}acetic acid 3 were patented as a potential drug for the treatment of metabolic bone diseases [24, 25] . Later, it was found out that they stimulate parathyroid hormone receptor-mediated cAMP formation and could be useful for the local and systemic treatment of rheumatoid arthritis, osteoarthritis, and degenerative arthrosis [24, 25] .
Trypanocidal activity of substituted rhodanine-3-acetic acids has been reported recently [26] . The only rhodanine acetic acid derivative that has been used clinically is the aldose reductase inhibitor epalrestat 4. It was marketed in Japan and used to slow eye damage associated with diabetes and to prevent diabetic peripheral neuropathy [1, 22, [27] [28] [29] . Aldose reductase is not the only enzyme inhibited by rhodanine carboxylic acids. It was found that many other enzymes are also inhibited by the derivatives of this structural class and may be responsible for their various biological effects [30] . Other rhodanine-based molecules have also been popular as small molecule inhibitors of numerous targets such as hepatitis C viral (HCV) NS3 protease [31] , antidiabetic mechanism [32] , aldose reductase [33] , -lactamase [34, 35] , histidine decarboxylase [36] , and JNK Stimulatory Phosphatase-1 (JSP-1) [37] . This section is a brief account on synthesis and biological effects and recent developments of newly prepared potential drugs based on nitrogen-sulphur containing heterocycles having rhodanine nucleus. (16-compounds) by 1,3-dipolar cycloaddition reaction of azomethine ylides (in situ generated by the reaction of sarcosine with isatin) with 5-arylidene-1,3-thiazolidine-2,4-dione and 5-arylidene-4-thioxo-1,3-thiazolidine-2-one derivatives as dipolarophiles. They performed molecular docking studies on 1FM9 protein and screened synthesized compounds for their antidiabetic activity on male Wistar rats (after alloxan treatment). The synthesized compounds exhibited attractive antidiabetic properties and are more effective than rosiglitazone in ameliorating stress conditions. 
Rhodanine as Antiapoptotic Agent.
Xing and his coworker synthesized, a series of BH3I-1 based dimeric modulators of 6. The overexpression of antiapoptotic Bcl-2 proteins which protects cells from apoptosis is one mechanism for tumours to acquire drug resistance. In this study they found dimeric modulators 7-8 have enhanced binding activity against antiapoptotic Bcl-2 proteins and proved dimerization of monomeric modulators is one practical approach to enhance the bioactivity of Bcl-2 antagonists [39] . Moorthy and his group [40] designed and synthesized 5-isopropylidiene derivatives of 5-benzilidene-3-ethyl rhodanine (BTR-1) 9, 3-dimethyl-2-thio-hydantoin (ITH-1) 10, and 3-ethyl-2-thio-2,4-oxazolidinedione (ITO-1) 11 and tested their chemotherapeutic properties. They found all the compounds induced cytotoxicity in a time-and concentrationdependent manner on leukemic cell line, CEM. Among these compounds, BTR-1 9 was found to be manifold more potent in inducing cytotoxicity than ITH-1 10 and ITO-1 11 with an IC50 value of <10 M and affected cell division by inducing a block at S phase, which finally led to the activation of apoptosis.
The same research group reported [41] the synthesis of 5-isopropylidene-3-ethyl rhodanine 12 by conventional and microwave-assisted method, and they found that rhodanine ITR 12 treatment led to cytotoxicity in leukemic cell line, CEM, by inducing apoptosis. [42] thiazolo [4,5- dlpyrimidines with rhodanines and investigated the obtained products (7 compounds with 60-80% yields) 13 for antimicrobial screening and they found antifungal activity against Aspergillus niger and Penicillium sp. with IZ 20-38 mm and MIC <50-<25 g/mL. They claimed compound 14 is the most active against Aspergillus niger while compound 15 is the most active against Penicillium sp.; and 5-fold less active than the standard antibiotic clotrimazole. They concluded that the presence of an alkyl group at position 3 of the thiazolopyrimidine ring 14 is superior to that of other aromatic substituents; also the introduction of an arylideneamino group at position 6 of 15 enhanced the antifungal activity. Opperman and his group disclosed [43] 
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Chen and his group synthesized [46] several hybrid compounds (19 compounds with 31-58% yields) 25 having International Journal of Medicinal Chemistry 5 chalcone and rhodanine-3-acetic acid units and tested these compounds for their antibacterial activity. They found some compounds presented great antimicrobial activities against Gram-positive bacteria (including the multidrug-resistant clinical isolates) as active as the standard drug (norfloxacin) and less active than oxacillin.
Tomasic et al. reported [47] the synthesis and antibacterial activity for a series of rhodanine-, rhodanine-N-acetic acid-, thiazolidine-2,4-dione-,barbituric-, and thiobarbituric acid-based compounds bearing an ylidene substituent at position 5. The most potent compound of the series, (Z)-5-(2,3,4-trifluorobenzylidene)rhodanine 26, inhibited the growth of S. aureus at 0.5 mg/mL and MRSA at 32 mg/mL. Sortino et al. reported [49] benzylidene-rhodanines 30 which act as antifungal agents. They evaluated that compounds 31 and 32 showed fungicidal activity and are the most active against Candida genus and C. neoformans including clinical isolates. Other compounds of this series showed a very good activity against dermatophytes.
Rhodanine as Antihepatitis C Virus (HCV) Agent.
Sing et al. disclosed [50] arylalkylidene rhodanines 33-34 inhibit HCV NS3 protease at moderate concentrations. They claimed these rhodanine derivatives are better inhibitors of serine proteases such as chymotrypsin and plasmin. They concluded that selectivity of arylmethylidene rhodanines 33-34 with bulkier and more hydrophobic functional groups increases by 13-and 25-fold towards HCV NS3 protease, respectively. [52] synthesis and evaluation of rhodanine-based compounds 36 as inhibitors of JSP-1. On SAR studies they demonstrated that stronger electron-withdrawing functional groups appended to the aryl-benzylidene position provided analogs with the greatest potencies as illustrated by compound 37. Compound 37 has also reversible and competitive bind with substrate and showed a high degree of enzyme selectivity against other phosphatases. [55] and evaluated a series of rhodanine derivatives 45 for their ability to inhibit oncolytic phosphatase (PRL-3). Benzylidene rhodanine derivative 45 showed good biological activity, while compound 46 is found to be the most active in this series exhibiting IC50 value of 0.9 Lm in vitro and showed a reduced invasion in cell-based assay. 
Pharmacological Developments in 2,4-Thiazolidinediones
The most commonly used antidiabetic agents have been sulfonylureas, metformin, and certain alphaglucosidase inhibitors and meglitinides. These agents increase insulin secretion from pancreatic -cells but sometimes induce severe hypoglycemia and weight gain [56] , and hyperinsulinemia is known to be a risk factor for ischemic heart disease [57] . In addition, high rates of both primary and secondary failure have been observed with these drugs [58] [59] [60] [61] . Therefore, drugs that ameliorate the insulin resistance without stimulating insulin release from -cells have been developed for the treatment of type 2 diabetes. Type 2 diabetes is a multifactorial disease defined by a high plasma glucose level and is characterized by both insulin resistance and impaired insulin secretion by pancreatic -cells [62] . The prototypical 2,4-thiazolidinedione, ciglitazone 47 was discovered [63] by Takeda Chemical Industries, Ltd., Japan, and has antihyperglycemic activity in insulin-resistant animal models, KKAy mice [64] , and Wistar fatty rats [65] but no effect in insulin-deficient animal models of diabetes [66, 67] . During structure-activity relationship studies on 2,4-thiazolidinediones and related compounds, they discovered highly potent compounds, such as pioglitazone 48 [68] and AD-5061 49 [69] . Since the discovery of ciglitazone 47, a number of pharmaceutical companies have been evaluating new 2,4-thiazolidinedione analogs as agents for improving insulin resistance. Troglitazone 50 [70] was launched first in the market but had been withdrawn because of liver toxicity and related deaths associated with the drug. Nowadays, two 2,4-thiazolidinedione class agents, pioglitazone 48 and rosiglitazone 51 [71] , have been clinically used. Furthermore, many companies are still endeavoring to find a new glucose-lowering agent [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] . Although the precise mechanism of action of these drugs remains unknown, a recent study suggests that antidiabetic thiazolidinediones interact with a family of nuclear receptors known as peroxisome proliferator-activated receptor (PPAR)- [85] . PPAR is one of a subfamily of PPARs encoded by independent genes. Three human PPARs, designated PPAR , PPAR , and PPAR , have been identified to date [86] [87] [88] . It was also observed that the potency for the activation of PPAR in vitro mirrored the in vivo glucose-lowering activity in diabetic ob/ob mice [89] . This would indicate that the major mechanisms of action of 2,4-thiazolidinediones involve PPAR . In case of those 2,4-thiazolidinediones already on the market, several side effects, such as anaemia, edema, and body weight gain, have been reported [90] . Therefore, search for new compounds with fewer side effects and a more advanced profile than existing drug molecules is the main focus of attention for chemists as well as for pharmacologists. Recent developments in the synthesis and evaluations of thiazolidinedione-based compounds for a variety of biological activities along with antidiabetes is discussed in the ongoing pages.
Thiazolidinedione as Antidiabetic Agent. Rakowitz et al.
synthesised [91] and tested several 5-benzyl-2,4-thiazolidinediones 52-53 as in vitro aldose reductase inhibitors (ARIs). Their evaluation shows N-unsubstituted 5-benzyl-2,4-thiazolidinediones 52 and (5-benzyl-2,4-dioxothiazolidin-3-yl)acetic acids 53 displayed moderate-to-high inhibitory activity levels. The insertion of an acetic chain on N-3 significantly enhanced AR inhibitory potency, leading to acids 53 which proved to be the most effective among the tested compounds. In addition, in N-unsubstituted derivatives 52 the presence of an additional aromatic ring on the 5-benzyl moiety was generally beneficial.
Madhavan et al. synthesized [92] and evaluated 2,4-thiazolidinedione derivatives of 1,3-benzoxazinone for their PPAR-and -dual activation. They obtained that a compound DRF-2519 (54), through SAR of TZD derivatives of benzoxazinone, has shown potent dual PPAR activation. In ob/ob mice, it showed better efficacy than the comparator molecules. In fat fed rat model, it showed significant improvement in lipid parameters, which was better than fibrates. 
DRF-2519
Na N Bozdaǧ-Dündar et al. prepared [93] a new series of chromonyl-2,4-thiazolidinediones 55 aiming to reduce diabetic complications especially which have effect on the cataract formation. The synthesized compounds were tested for their ability to inhibit rat kidney AR by an in vitro spectrophotometric assay. Compound 56 showed the highest inhibitory activity. They concluded that the increasing inhibitory effect of compounds 55 might depend on the acetic acid side chain of 2,4-thiazolidinedione, and these compounds especially 56 could display therapeutic potential [102] synthesis of methylsulfonamide-substituted 2,4-thiazolidinedione (6 compounds) 75 and found 76 to be a potent (EC50 = 0.01 mM, IA = 1.19) and selective (more than 110-fold over 1 and 2 agonist activity) 3 agonist. This compound has also been proven to be active and selective in an in vivo mode. 
Conclusion
In recent past, a variety of molecules based on rhodanine and thiazolidinedione have been synthesized and evaluated with improved pharmacological activities. Due to wide range of pharmacological activities and clinically used 2,4-thiazolidines, these molecules have attracted much attention and encouraged the chemists and biologists to be extensive investigations or molecular manipulations, and as a result further improved protocol with better observation is still under progress.
